trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['biomarker']
 5/ t-dxd: nice to see her2mut also in plenary: in our ,if multiple tumors efficacy w/ a biomarker good chance for multiple(cross)tumor success needs expansion cohorts &amp; novel: 
Translational Medical Oncologist (Biomarkers, Toxicities, Health Outcomes, Clinico-Genomic Big Data) @OncoAlert. Motto: "Let's make a difference". Views mine.